SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luckydog88 who wrote (907)3/13/2025 4:18:36 PM
From: bobbseytwins20018 Recommendations

Recommended By
CCS648
Davidoff
erippetoe
Fitzhughlaw
JJINV

and 3 more members

   of 1229
 
A Quick Look at D. Boral analyst Jason Kolbert and his qualifications on Perplexity.com is in itself pretty impressive to us. Somehow he has survived 20 years in Biotech, which is unusual, and he seems very well qualified with real experience on both the buy and sell sides and shows an extensive background in oncology. His $30 IBRX target may be extreme, because he could just as easily call it at $5 or $6, so what is his motivation? We think he believes he has something special here, and IBRX is helping by showing some genuine science and execution skills recently. It's obvious that Kolbert is a true fan of PSS and the rationale behind Acktiva, otherwise why would he get so far out on a limb? We like our position and his persistent strong recommendations.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News